Age-specific predictors of cervical dysplasia recurrence after primary conization: analysis of 3,212 women.


Journal

Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 30 12 2019
revised: 31 03 2020
accepted: 06 04 2020
entrez: 19 8 2020
pubmed: 19 8 2020
medline: 2 9 2021
Statut: ppublish

Résumé

This study aimed to identify predictors of recurrence/persistence of cervical intraepithelial neoplasia grade 2+ (CIN2+) lesion (r-CIN2+) after primary conization. Retrospective analysis involving all consecutive women having conization for CIN2+ between 1998 and 2018. The risk of r-CIN2+ was assessed using Kaplan-Meier and Cox models. Data of 3,212 women were retrospectively identified. After a mean follow-up of 47 (±22.2) months, 112 (3.5%) patients developed r-CIN2+. Mean time interval between prior conization and diagnosis of r-CIN2+ was 26.2 (±13.2) months. Via multivariate analysis, presence of high-risk human papillomavirus (HPV) types at the time of CIN2+ diagnosis, hazard ratio (HR)=3.40 (95% confidence interval [CI]=1.66-6.95) for HPV16/18 and HR=2.59 (95% CI=1.21-5.55) for HPV types other than 16/18, positive margins at primary conization, HR=4.11 (95% CI=2.04-8.26) and HPV persistence after conization, HR=16.69 (95% CI=8.20-33.9), correlated with r-CIN2+, independently. Considering age-specific HPV types distribution, we observed that HPV16/18 infection correlated to an increased risk of r-CIN2+ only in young women (aged ≤25 years; p=0.031, log-rank test); while in the older population (>25 years) HPV type(s) involved had not impact on r-CIN2+ risk (p>0.200, log-rank test). HPV persistence is the main factor predicting r-CIN2+. Infection from HPV16/18 has a detrimental effect in young women, thus highlighting the need of implementing vaccination against HPV in this population. Further prospective studies are warranted for tailoring clinical decision-making for post-conization follow-up on the basis of risk factors.

Identifiants

pubmed: 32808492
pii: 31.e60
doi: 10.3802/jgo.2020.31.e60
pmc: PMC7440983
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e60

Informations de copyright

Copyright © 2020. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.

Déclaration de conflit d'intérêts

No potential conflict of interest relevant to this article was reported.

Références

Gynecol Oncol. 2019 Aug;154(2):345-353
pubmed: 31242966
Lancet Public Health. 2016 Nov;1(1):e8-e17
pubmed: 29253379
Eur J Cancer Prev. 2019 Mar;28(2):81-86
pubmed: 29360648
Gynecol Oncol. 2008 Mar;108(3):549-54
pubmed: 18177929
Gynecol Oncol. 2019 Aug;154(2):354-359
pubmed: 31176553
Eur J Cancer Prev. 2019 Sep;28(5):435-440
pubmed: 30489353
Lancet. 2019 Jan 12;393(10167):169-182
pubmed: 30638582
Eur J Cancer. 2020 Mar;127:207-223
pubmed: 31980322
PLoS One. 2015 Dec 01;10(12):e0142868
pubmed: 26624896
Lancet Oncol. 2019 Feb;20(2):229-238
pubmed: 30658933
Eur J Obstet Gynecol Reprod Biol. 2012 Nov;165(1):86-90
pubmed: 22771223
Lancet Oncol. 2017 Dec;18(12):1665-1679
pubmed: 29126708
Gynecol Oncol. 2018 Nov;151(2):229-234
pubmed: 30197061
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301

Auteurs

Giorgio Bogani (G)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. giorgio.bogani@istitutotumori.mi.it.

Ciro Pinelli (C)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Valentina Chiappa (V)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Fabio Martinelli (F)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Salvatore Lopez (S)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Antonino Ditto (A)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Francesco Raspagliesi (F)

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH